Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02000895 · ClinicalTrials.gov registry record

BLOOM: Biological Legacy of Origin in Mother-Infant Dyads

A clinical trial of Cardiovascular Diseases and Chronic Kidney Diseases, sponsored by University of Miami.

Recruiting
Registry status
300
Enrollment target
1
Study location

NCT02000895 is a study of Cardiovascular Diseases and Chronic Kidney Diseases that is actively recruiting participants, run by University of Miami. The registered enrollment target is 300 participants, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02000895, a study of Cardiovascular Diseases and Chronic Kidney Diseases, is actively recruiting participants, sponsored by University of Miami.

RECRUITING
Registry status
300 participants
Enrollment target
1
Study location

Study Summary

Infants born preterm and of low birth weight are known to be at increased risk for early onset of cardiovascular and renal disease in adult life. This has been related to low nephron mass due to inadequate or early termination of glomerulogenesis in utero and during the perinatal period. Risks for subsequent development of hypertension and kidney disease include proteinuria, excessive weight gain during early life with insulin resistance and supplemental high calorie feedings. The long-term goal is for early diagnosis of those infants who are at risk for future development of hypertension and kidney disease so that the investigators might intervene to potentially avert progression to adult disease. The objective of this clinical trial is to acquire data on the natural history of neonatal kidney function and size in infants born preterm during the first 2 years of life. This will be done through the use of standard serum and urine markers as well as non-invasive ultrasound technology. The central hypothesis of this clinical trial is that a subgroup of patients born preterm and of low birth weight will demonstrate early markers of kidney injury including elevated serum cystatin C, proteinuria and low kidney size. This hypothesis has been formulated on the basis of preliminary data from our group studying this question retrospectively in older children born prematurely who have developed overt kidney disease. The rationale for the proposed research is to develop early serum and demographic markers of pre-clinical kidney disease so that early intervention can occur. The proposed clinical trial is innovative because it will investigate the risk factors for kidney dysfunction at a pre-clinical stage with the idea of gaining more knowledge regarding therapeutic interventions. In addition, the study will assess serum cystatin C as a surrogate test for glomerular filtration rate which could indicate worsening kidney function at an earlier stage than serum creatinine. The pr

Study Locations (1)

Florida

  • University of Miami/ Holtz Children's Hospital - Miami

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2011-07-23
Est. Completion 2029-01-01

Sponsor

University of Miami

721 total trials

What the Registry Record Tells You About NCT02000895

The ClinicalTrials.gov registry entry for NCT02000895 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT02000895 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT02000895 about?

NCT02000895 is a clinical study titled "BLOOM: Biological Legacy of Origin in Mother-Infant Dyads". Infants born preterm and of low birth weight are known to be at increased risk for early onset of cardiovascular and renal disease in adult life. This has been related to low nephron mass due to inadequate or early termination of glomerulogenesis in utero and during the perinatal period. Risks for s...

What is the current status of trial NCT02000895?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2011-07-23. Estimated completion is 2029-01-01.

What conditions does trial NCT02000895 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Chronic Kidney Diseases.

Who is sponsoring clinical trial NCT02000895?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02000895 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.